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Physiologically, vascular endothelial growth factors (VEGF) and their receptors 
(VEGFR) play a critical role in vascular development, neogenesis, angiogenesis, 
endothelial function and vascular tone. Pathologically, VEGF-VEGFR signaling 
induces dysregulated angiogenesis, which contributes to the growth and spread of 
tumors. The development of VEGF-VEGFR inhibitors (VEGFIs) has thus proven to 
be a valuable strategy in the management of a number of malignancies, yielding 
improved survival outcomes. Not surprisingly, VEGFIs are now standard of care as 
first-line monotherapy for some cancers and the scope of this class of drugs is 
growing. However with the promise of improved outcomes, VEGFIs also led to 
clinically relevant toxicities, especially hypertension and cardiovascular disease 
(CVD). As such, cancer patients treated with VEGFIs may have improved cancer 
outcomes, but at the cost of an increased risk of CVD. Indeed, dose intensity and 
protracted use of these drugs can be limited by cardiovascular side effects and patients 
may require dose reduction or drug withdrawal, thus compromising anti-cancer 
efficacy and survival.  Here we summarize the vascular biology of VEGF-VEGFR 
signaling and discuss the cardiovascular consequences and clinical impact of VEGFIs. 
New insights into molecular mechanisms whereby VEGFIs cause hypertension and 
heart disease are highlighted. 
A primer in vascular biology and signaling of VEGF  
VEGFs, of which there are 4 isoforms (VEGFA, VEGFB, VEGFC, VEGFD), signal 
through VEGFR tyrosine kinases, and are critically involved in the development and 
function of the vasculature (1). VEGFs are produced by endothelial cells, fibroblasts, 
podocytes and cancer cells. Of the 3 VEGFR subtypes (VEGFR1, VEGFR2, 
VEGFR3), VEGFR2 is the primary receptor through which VEGF, especially 
VEGFA, signals in endothelial cells. VEGFs also bind to neuropilin receptors and to 
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heparin sulphate proteoglycans. Ligand-receptor binding promotes receptor 
dimerization and phosphorylation of receptor tyrosine kinases that trigger intracellular 
signaling with acute non-genomic effects, such as endothelial permeability and 
vasodilation, and chronic genomic responses, including cell differentiation, survival 
and proliferation (1) (figure 1). VEGFR2 signaling is also activated through non-
ligand processes, such as shear stress and stretch, that stimulate non-canonical 
signaling through cytoplasmic tyrosine kinases (e.g. c-Src) (1,2). Multiple 
mechanisms regulate VEGFRs, including protein expression, ligand availability, co-
activators, intracellular tyrosine kinases/phosphatases, intracellular degradation and 
recycling and cross-talk between VEGFs and VEGFR subtypes (1). 
VEGFR2 activation triggers pathways essential for endothelial biology, 
including PLC-DAG-IP3 and downstream Ca
2+ and ERK1/2 signaling, important in 
arteriogenesis, neogenesis and angiogenesis, through regulation of cell migration, fate 
specification, proliferation and contraction/dilation (1). VEGF-VEGFR2-mediated 
increase in intracellular free Ca2+ concentration ([Ca2+]i) influences calcineurin-
induced nuclear translocation of NFAT, which downregulates VEGFR1, thereby 
further increasing VEGFR2 signaling, because VEGFR1 negatively regulates 
VEGFR2 (3). VEGFR2 phosphorylation also promotes activation of small GTPases, 
Src, stress kinases and sphingosine-1-phosphate that influence cytoskeletal 
organization, cell morphology, adhesion, migration and cell-cell interaction, 
important in endothelial integrity (1-4). 
In addition to regulating vascular development and permeability, VEGF-
VEGFR2 influences vascular tone by modulating vasorelaxation. VEGFR2-mediated 
activation of PI3K-AKT leads to eNOS phosphorylation, increased NO generation 
and consequent vasodilation (1,5). Other vasodilatory pathways include VEGF-
 4 
 
stimulated COX-stimulated production of the vasodilator prostacyclin I2 (1) VEGF 
also inhibits endothelial production of the potent vasoconstrictor endothelin-1 (ET-1) 
(6). Accordingly, physiological VEGF-VEGFR2 signaling maintains vascular tone by 
balancing NO- and prostacyclin-induced vasodilation and ET-1-regulated 
vasoconstriction.  
VEGF signaling as a target for anti-angiogenic and anti-cancer therapy. 
Angiogenesis, the formation of new blood vessels from pre-existing vasculature, is 
critical for tumor growth and metastasis. This process is regulated by growth factors 
of which VEGFA-VEGFR2 plays a key role (7). Inhibition of angiogenesis, by 
targeting VEGF-VEGFR signaling, has revolutionised cancer therapy with improved 
outcomes in some previously untreatable cancers. Four major classes of VEGFI are 
currently used clinically, including monoclonal VEGF antibodies (bevacizumab), 
monoclonal VEGFR antibodies (ramucirumab), soluble decoy receptors (VEGF traps) 
(aflibercept) and small molecule VEGFR tyrosine kinase inhibitors (TKI) (sunitinib, 
cabozantinib, pazopanib, axitinib, vandetanib, regorafenib) (8,9) (figure 2). Since 
endothelial cells are physiologically quiescent, no adverse effects during anti-
angiogenesis therapy were expected. However, clinical observations demonstrated 
that VEGFIs are associated with unexpected cardiovascular toxicity, especially 
hypertension. 
Cardiovascular toxicities of VEGF inhibition 
VEGF inhibitors are associated with an increased incidence of various cardiovascular 
pathologies including hypertension, ischaemic heart disease, heart failure, QT-interval 
prolongation and thromboembolism (10-12). Of these, hypertension is the most 
commonly reported toxicity in VEGFI trials, an effect that may limit anti-cancer 
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treatment (9,10). Cardiovascular effects of VEGFIs may be severe with an associated 
increased risk of reversible leukoencephalopathy and fatal cardiovascular events (13).  
Inhibition of VEGF signaling has also been implicated in the pathophysiology 
of preeclampsia, where there is an increased production of placental factors including 
a splice variant of VEGFR-1 (soluble Fms-like tyrosine kinase 1 (sFlt-1)) (14). sFlt-1, 
by binding VEGF, leads to reduced VEGFR activation and consequent endothelial 
dysfunction.  
VEGF inhibition and hypertension 
The magnitude of VEGFI-induced hypertension is significant, with almost every trial 
reporting an increase in blood pressure (BP),  often >150/100 mmHg (9,10,15). 
Development of hypertension is dose-dependent and rises to ≈100% when VEGFIs 
are combined. Pre-existing hypertension, older age and overweight are important risk 
factors for development of VEGFI-induced hypertension (16).  
The risk of hypertension was found to be 20–30% higher than expected for 
bevacizumab (17). Home BP monitoring might lead to even higher rates of 
hypertension (especially of lower grades) than clinic measurements (17). Ambulatory 
BP monitoring (ABPM) revealed that VEGFI-induced BP increase occurs rapidly, 
within hours of commencement of therapy, and >90% of patients had an increase in 
BP.(18,19).In sunitinib-treated renal cell carcinoma patients the average BP increase 
was 14/11 mmHg in the first and 22/17 mmHg in the second week, a response that 
was sustained until therapy withdrawal, when BP decreased rapidly (18). ABPM 
studies further demonstrated that circadian BP patterns are lost or attenuated, a 
response that increases risk of hypertension-associated cardiovascular events.  
In the general population, BP monitoring and treatment are important for 
primary (and secondary) prevention of CVD and long-term events. Previously this 
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was not a priority in cancer patients with limited life expectancy. However with 
improved survival outcomes and chronicity of VEGFI treatment, BP monitoring and 
management are essential. For example, patients with chronic myeloid leukemia, are 
treated chronically with ponatinib, exposing them to increased hypertension and 
CVD. 
VEGFI-induced hypertension does not seem to be a risk factor for proteinuria 
(19). This agrees with experimental studies demonstrating that proteinuria and renal 
injury, including glomerular ischemia, develop first and mainly as a function of 
VEGFI dose (20). Hypertension occurs earlier and at lower doses of VEGFI therapy, 
and these dynamics also suggest that renal dysfunction is not the initial pro-
hypertensive insult  either (20). However, VEGFI is associated with a rightward shift 
of the renal pressure-natriuresis curve and impaired sodium excretion with consequent 
fluid retention and salt-dependent hypertension.  
The acuteness of the BP increase caused by VEGFI, and the rapid BP 
reduction upon drug withdrawal suggest that functional changes in vascular tone 
(decreased vasodilation/increased vasoconstriction) may be the key trigger of the 
hypertensive response. These vascular phenomena reflect direct actions of VEGFI and 
as such are on-target effects. Hypertension may thus  serve as a biomarker of efficacy 
of VEGFI therapy, and indeed, studies have demonstrated better outcomes for cancer 
patients who develop hypertension with VEGFI treatment (21).  
Mechanism of hypertension during VEGF inhibition 
Mechanisms underlying VEGFI-induced hypertension remain unclear. Carter et al. 
showed that administration of four different multi-targeted tyrosine kinase inhibitors 
(RTKIs) in conscious rats induced a BP rise accompanied by significant 
vasoconstriction in the mesenteric and hindquarter vascular beds, but not in the 
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kidney (22). These findings support previous observations that vasoconstriction rather 
than cardiosuppression or renal dysfunction underlies the VEGFI-induced BP rise. 
The vasoconstrictive response to VEGFIs likely relates to reduced levels of the 
vasodilator NO due to inhibition of endothelial nitric oxide synthase (eNOS)-induced 
NO production. In support of this, in healthy volunteers, intra-arterial infusion of 
bevacizumab in the forearm acutely reduced the vasodilator response to acetylcholine 
(23). In conscious rats the dose-dependent increase in sunitinib-induced BP elevation 
was associated with a dose-dependent decrease in urinary excretion of the NO 
effector molecule cGMP (24). However some clinical studies failed to show a role of 
decreased NO availability as an underlying cause of the vasoconstriction and BP rise 
caused by VEGFIs (5).  
Another mechanism that has been implicated in VEGFI-induced hypertension 
is increased production of the potent vasoconstrictor ET-1. Sunitinib is associated 
with raised levels of circulating ET-1, both in patients and in rats (5,25). Increased 
plasma ET-1 concentration has also been reported in patients treated with regorafenib 
as well as in preeclamptic patients with elevated sFlt-1 levels (25). Proof that an 
activated ET-1 system is instrumental, at least during the initial sunitinib-induced BP 
rise, has been obtained with ET-1 receptor (ETR) antagonists. In conscious rats, co-
administration of the ETR antagonist macitentan prevented hypertension caused by 
sunitinib (26). In this same model sildenafil, a specific inhibitor of the enzyme 
phosphodiesterase 5, responsible for the breakdown of cGMP to 5’-GMP, did not 
lowerof BP. In swine exposed to sunitinib for one week the elevated BP could be 
returned to pre-sunitinib levels with the ETR antagonist tezosentan (27). 
Unexpectedly, in this same model acute administration of the NOS inhibitor L-
NMMA was associated with an aggravation of BP elevation. Furthermore, anti-
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oxidants given after sunitinib for one week were associated with an attenuated BP 
decline compared to their response pre-sunitinib administration, questioning a 
potential role for oxidative stress in VEGFI-induced hypertension (27). However not 
all studies have shown an ET-1-dependent effect. Bosentan, the ETAR/ETBR blocker 
failed to reduce BP in cediranib-treated rats (22).  
Another potential mechanism whereby VEGFIs influence vascular tone and 
BP responses might relate to changes in [Ca2+]i, a key player regulating vascular 
contraction. VEGFI may inhibit Ca2+ channel activation, leading to increased [Ca2+]I 
(1-4), which is critically involved in triggering vascular contraction. 
Rarefaction (decreased microvessel number) is another putative mechanism 
underlying the rise in vascular resistance and BP associated with VEGFI (28). The 
fact that BP increases within hours after initiation of VEGFI argues against a 
pathophysiological role for structural rarefaction in the developmental phase of 
hypertension. Since rarefaction is reversible upon drug withdrawal (28), it may be a 
functional phenomenon due to profound vasoconstriction, at least acutely. Structural 
rarefaction may contribute to hypertension during prolonged VEGFI. It should be 
highlighted that for a relatively small increase in vascular resistance an extensive 
degree of rarefaction is required. Furthermore, hypertension itself may cause 
rarefaction (29).  
Rat studies have shown that the VEGFI-induced BP increase is aggravated by 
a high sodium diet and accompanied by a leftward shift of the pressure-natriuresis 
curve, indicating that the BP rise is salt-sensitive (30). Decreased NO production in 
renal proximal tubular cells, impairing vasa recta dilatation and consequently 
pressure-natriuresis may underlie this salt-sensitivity.  In response to a high salt diet, 
sodium and chloride accumulate in the skin in excess of water, leading to a hypertonic 
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interstitial fluid compartment. In response to this hypertonicity, dermal mononuclear 
phagocytes system (MPS) cells produce the transcription factor tonicity-responsive 
enhancer-binding protein that initiates expression and production of VEGF-C (31). 
VEGF-C in turn stimulates formation of lymph vessels to clear excessive electrolytes. 
Interruption of this pathway in rodents is associated with salt-sensitive hypertension 
(30). Hence, impairment of lymphangiogenesis, a feature of most VEGFIs, may 
contribute to salt-sensitive hypertension following VEGFI. In high salt-fed 
normotensive rats sodium and chloride accumulation in the skin was associated with 
an exaggerated sunitinib-induced BP elevation. Skin MPS cell density increased 
during high salt diet and sunitinib administration, but no further increment was seen 
with combined salt and sunitinib. A high salt diet also increased skin 
lymphangiogenesis, while sunitinib mildly reduced lymphangiogenesis, both during a 
normal and high salt diet. These data suggest that sunitinib induces salt-sensitive 
hypertension, but that impaired skin lymphangiogenesis is unlikely to play an 
important role therein. The clinical significance of these findings awaits clarification. 
Renal injury, hypertension and VEGF inhibition 
VEGF inhibition is associated with kidney injury, commonly reflected by proteinuria 
and occasionally by an increased serum creatinine. Different mechanisms account for 
the BP rise and kidney injury (32). In sunitinib-induced hypertensive rats, there was a 
discrepancy between the BP-lowering and antiproteinuric effects of antihypertensive 
agents (26). Captopril and sildenafil prevented proteinuria without effect on BP, 
whereas amlodipine prevented development of hypertension without antiproteinuric 
effect. In this model the ETR antagonist macitentan prevented hypertension and 
proteinuria, supporting recent studies suggesting that ET-1 not only plays a role in 
VEGFI-induced hypertension but also in kidney injury (26).  
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Glomerular endotheliosis, also seen in preeclampsia, and thrombotic 
microangiopathy (TMA) are well-established histological abnormalities associated 
with VEGFI. In ≈50% of patients, TMA is restricted to the kidney (33). Kidney 
biopsies of 100 patients with proteinuria and renal dysfunction following VEGFI 
showed TMA in 73 and minimal change and collapsing focal segmental 
glomerulosclerosis in 27 patients (33). Almost all patients with TMA were treated 
with bevacizumab or VEGF-trap, whereas all but one patient with the alternative renal 
histopathology were treated with RTKIs. A high salt intake exacerbates the severity of 
VEGFI-associated glomerular injury 
VEGF inhibition, sFlt-1 and preeclampsia  
Preeclampsia is associated with increased production of placental factors, including 
sFlt-1, soluble endoglin, and inflammatory cytokines (34), which cause activation of 
endothelial cells and generalized endothelial dysfunction. sFlt-1, a soluble form of 
VEGF and PlGF receptors, binds to free VEGF and PlGF, thereby reducing their 
bioavailability for their respective membrane receptors. This leads to inhibiton of 
VEGF and PlGF signaling and disruption in the balance between pro- and anti-
angiogenic factors, which not only affects the growth and development of the placenta 
and fetus, but also the function of endothelial cells and the kidney (34). It thus offers 
an explanation for both hypertension and renal dysfunction occurring in preeclampsia. 
The hypertension, proteinuria and glomerular endotheliosis occurring during VEGFI 
is similar to that observed in preeclampsia and accordingly, some authors have termed 
the condition as a  ‘preeclampsia-like’ syndrome (35). In support of this, preeclamptic 
women and VEGFI-treated cancer patients exhibit hypertension with elevated ET-1 
levels, which correlate with the degree of VEGF inhibition, represented by serum 
sFlt-1 levels or VEGF inhibitor dose. Animal models replicating the various aspects 
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of human preeclampsia support the sFlt-1/ET-1 upregulation, and show that ETR 
antagonism alleviates preeclampsia symptoms to the same degree as it prevents the 
preeclampsia-like symptoms during VEGFI (25,36). The exact cause(s) of the ET-1 
rise remain unclear, but in addition to VEGF inhibition per se, placenta-derived 
soluble endoglin has been suggested to induce endothelial ET-1 production (37). The 
net clinical effect of VEGF inactivation (excess sFlt-1 in preeclampisa) and VEGF 
inhibition (VEGF inhibitors) is similar . 
Cardiotoxic effects of VEGF inhibitors 
Although hypertension is the most common cardiovascular side effect of VEGFIs, 
these drugs are also associated with cardiac toxicity.  
Left Ventricular Systolic Dysfunction. While cardiac toxicity of VEGFIs may 
manifest as arrhythmia and atherothrombosis, a more pressing concern is their 
association with left ventricular systolic dysfunction (LVSD) and heart failure 
(38,39). Most cardiotoxic effects of VEGFIs were neither predicted nor observed 
prior to their clinical introduction. This may reflect a relative lack of robust 
assessment in early clinical trials and an under-appreciation that many patients with 
cancer, who might not have been eligible for inclusion in trials, have factors 
predisposing them to potential cardiotoxicity, such as pre-existing hypertension, 
diabetes and coronary artery disease. Furthermore, many patients have had prior 
treatment with other cancer chemotherapy agents or radiotherapy predisposing to 
cardiotoxicity.  
The clinical spectrum of VEGFI-associated myocardial toxicity ranges from 
asymptomatic LVSD to heart failure or cardiogenic shock and death (38-40). 
Unfortunately, obtaining an accurate incidence of LVSD or heart failure with VEGFI 
is challenging and the reported incidence may actually underestimate the true scale of 
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the problem. There is often overlap between symptoms that potentially reflect heart 
failure with those related to cancer and not the heart. For example, breathlessness, 
fatigue and edema are often reported by patients and attributed to cancer and not the 
heart (38). In addition, imaging of left ventricular function is not a consistent feature 
in VEGFI trials. Consequently, asymptomatic LVSD during the time-limited trial 
period is usually not reported or assessed.   
The largest meta-analysis of TKI trials included 10,647 patients (39). The 
relative risk for the development of asymptomatic LVSD or heart failure was 2.69 for 
those treated with TKI versus those not receiving these agents (39,40). Notably, the 
risk of developing LVSD or heart failure for specific TKIs (e.g. axitinib) was similar 
to relatively non-specific TKIs (sunitinib, sorafenib, vandetanib and pazopanib) 
(40,41).  
A meta-analysis of 3,784 patients receiving bevacizumab for breast cancer 
revealed an overall incidence of heart failure of 1.6% in bevacizumab-treated patients 
versus 0.4% in placebo-treated individuals (42) and similar findings were observed 
for sunitinib (41). Retrospective data from VEGFI-treated patients revealed a similar 
incidence of heart failure. These ‘real world’ patients were also screened for LV 
dysfunction or rise in brain natriuretic peptide. 27% of patients had elevated NT-
proBNP and/or decline in left ventricular ejection fraction during treatment (43), a 
proportion similar to the observed 28% incidence of reduced LV ejection in a 
randomised controlled trial with sunitinib. 
Acute Coronary Syndrome. Over and above the pro-coagulant effects of malignancy, 
thrombosis risk associated with VEGFI is increased, with greater tendency to arterial 
thrombosis than venous thrombo-embolism. In a meta-analysis of 38,078 patients (72 
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trials), there was a 3.5-fold increase in myocardial infarction risk (44). Although this 
relative increase in risk may appear striking, this has to be taken in context and the 
absolute increase in risk for myocardial infarction for these patients was only 0.8%.   
Bevacizumab was associated with a 2.1-fold increase in the risk of ‘high-grade’ 
cardiac ischemia and arterial thrombotic events have been reported consistently (45). 
These bevacizumab-associated effects are particularly notable in patients >65 years 
and with a history of thromboembolism (45). In a phase I/II sunitinib trial, 1% of 
patients suffered myocardial infarction whilst 1% suffered cardiac death (44). In a 
randomised trial of sorafenib-treated patients 3% suffered myocardial ischaemia or 
infarction (46). The fact that VEGFIs are also associated with a paradoxical increase 
in the bleeding risk poses a challenging dilemma when considering anti-platelet 
therapy to reduce risk of myocardial ischaemia in patients treated with VEGFIs.  
Risk factors for the development of VEGFI-associated LV dysfunction are 
poorly understood, but a history of heart failure or coronary artery disease, pre-
existing hypertension, increasing age, lower body mass index and previous or 
concurrent treatment with other cardiotoxic agents may be important (47). Neither 
dose nor treatment duration has been shown to influence cardiotoxicity risk (48).  
Pathophysiology of VEGF inhibitor-associated cardiotoxicity 
Pathophysiological mechanisms underpinning myocardial toxicity of VEGFI have not 
been fully investigated. While hypertensive effects of VEGFI are likely important, 
alterations in cardiac energy generation through AMP-kinase inhibition and 
mitochondrial dysfunction appear central (49),  as well as effects related to inhibition 
of VEGF, PDGFR and c-Kit pathways (40). These changes either evoke reduced 
contractility or render the myocardium more vulnerable to effects of subsequent or 
co-existent insults, including hypertension. TKIs act at a raft of different pathways 
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both ‘on-target’ (i.e. present in both the cancer and the heart) and ‘off-target’ 
bystander kinases, which are unintended drug targets resulting from limited selectivity 
of these drugs (40). On-target effects may lead to direct cardiac toxicity or an 
inadequate compensatory response to myocardial stress. VEGF is critically involved 
in the compensatory hypertrophic response to myocardial stress, including that 
provoked by hypertension. Interruption of normal VEGF function with VEGFI 
accelerates development of left ventricular dilation in response to aortic constriction-
related pressure overload in mice (50) and murine VEGF120 gene knockout models 
have impaired cardiac contractile function and decreased myocardial angiogenesis 
(50). VEGF-A mRNA and protein are decreased in myocardial biopsy specimens 
from patients with non-ischaemic cardiomyopathy and reduced VEGF-A mRNA 
expression is also associated with rarefaction in these samples thus contributing to 
tissue hypoxia and activation of hypoxia-inducible factors.   
Electron microscopy of endomyocardial biopsies from patients with VEGFI-
associated heart failure demonstrated mitochondrial abnormalities but not apoptosis or 
fibrosis, suggesting a reversible process (43). Cardiotoxic effects of VEGFI are now 
considered to be at least partially reversible and routine monitoring of LV function in 
patients receiving these drugs should become routine clinical practice.  
Conclusions 
The scale of the clinical problem of VEGFI-induced hypertension and CVD is 
growing with an increasing number of cancer patients requiring these anti-angiogenic 
drugs for treatment. Moreover, cancer usually occurs in older individuals who are 
more susceptible to hypertension and CVD. Consequently increased usage of VEGFI, 
coupled with older cancer patients already at risk for cardiovascular events, means 
that the associated increased risk will not only negatively influence quality of life, but 
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also represents a potentially significant economic and health-care burden that will 
impact the emerging ‘epidemic of cancer and cardiovascular disease’ (51). Currently, 
exact causes for VEGFI-induced hypertension and cardiotoxicity remain unclear, 
although advances in the field have elucidated the potential role of impaired 
vasorelaxation/vasoconstriction, renal dysfunction, rarefaction and ET-1 
hyperactivation. Further research is urgently needed to fully understand molecular 
mechanisms whereby inhibition of VEGF signaling induces cardiovascular injury, 
with the hope that disease-targeted approaches will prevent hypertension and CVD 
without negatively impacting on beneficial anti-cancer VEGFI therapeutic effects. 
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Figure legends 
 
Figure 1.  
Diagram demonstrating signalling pathways induced by VEGFR activation. VEGFR 
is activated by VEGF binding and by non-ligand mechansims (shear stress, stretch). 
Both genomic and non-genomic pathways are stimulated leading to endothelial cell 
growth, differentiation, migration, adhesion and vasodilation. p, phosphorylation site 
of VEGFR tyrosine kinase; eNOS, endothelial nitric oxide synthase; NO, nitric oxide. 
 
Figure 2.  
Schematic illustrating possible pathophysiological processes whereby VEGF-VEGFR 
inhibition contributes to the development of hypertension and preeclampsia. Four 
major classes of VEGF-VEGFR inhibitors, including monoclonal VEGF antibodies, 
anti-VEGFR2 antibodies, soluble decoy receptors (VEGF-traps) and small molecule 
VEGFR tyrosine kinase inhibitors (TKI) are used clinically as anti-angiogenesis drugs 
in cancer. In pregnancy, placenta-derived soluble fms-like tyrosine kinase 1 (s-Flt), 
acts as a VEGF-trap reducing free VEGF availability for binding to VEGFR2R. These 
processes result in reduced VEGFR signaling and consequent reduction in production 
of vasodilators (NO and PGI2), increased production of vasoconstrictors (ET-1), 
oxidative stress and rarefaction, resulting in increased vascular tone and arterial 
remodeling. Reduced pressure natriuresis and impaired lymphatic function contribute 
to volume overload. p, phosphorylation site of tyrosine kinase; ROS, reactive oxygen 
species; NO, nitric oxide; ET-1, endothelin-1; Ab, antibody; ECF, extracellular fluid; 
CVD, cardiovascular disease, PGI2, prostaglandin I2 
 
 
 
